Non-Hodgkin Lymphoma
Research from University of the Free State in the Area of Non-Hodgkin Lymphoma Published
Published in Drug Week, January 27th, 2012
2012 JAN 27 -- According to the authors of recent research published in the journal Clinical Pharmacokinetics, "Bortezomib, an antineoplastic agent with proteasome inhibitory activity, is extensively metabolized by the hepatic microsomal cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C19. Drugs that affect these enzymes may therefore have an impact on the pharmacological profile of bortezomib."
"This study evaluated the effects of co-administration of a potent CYP3A4 inducer (rifampicin [rifampin]) and a weak CyP3A4 inducer (dexamethasone) on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib. Patients aged >= 18 years with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2012-01-27)
More Articles from Drug Week
- Drug Abuse
Chattanooga Law Firm in Step With Governor Haslam's Public Safety Action Plan - Adverse Drug Reactions
Data on Adverse Drug Reactions Described by T. Sakaeda et al - Depression
Data on Depression Discussed by Researchers at School of Public Health - Cancer Therapy
Findings from Johns Hopkins University Advance Knowledge in Cancer Therapy - Drug Development
Findings from Y. Shan and Co-Authors Broaden Understanding of Drug Development - Addiction Medicine
How the brain puts the brakes on the negative impact of cocaine - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
